FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to cyclic azaindole-3-carboxamides of formula (I) in any of its stereoisomeric forms or in the form of a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them: 
wherein A is specified in O, S and C(Ra)2; Ra is specified in hydrogen and (C1-C4)-alkyl wherein the two groups Ra are independent from each other and may be identical or different; R is specified from hydrogen, (C1-C4)-alkyl, hydroxy-(C1-C4)-alkyl-, (C1-C4)-alkyl-O-(C1-C4)-alkyl-, phenyl-(C1-C4)-alkyl-, (C1-C4)-alkyl-O-CO-CuH2u- and R1-NH-CO-CuH2u-, wherein all the groups R are independent from each other and may be identical or different; R1 is specified from hydrogen, (C1-C4)-alkyl and H2N-CO-(C1-C4)-alkyl-; R10 is specified from hydrogen, (C1-C6)-alkyl-O-CO-; R20 is specified from phenyl which is optionally substituted by one or more identical or different substitutes specified in halogen, (C1-C4)-alkyl and (C1-C4)-alkyl-O-; R30 is specified from (C3-C7)-cycloalkyl and phenyl, wherein phenyl is optionaly substituted by one or more identical or different substitutes specified in halogen and (C1-C6)-alkyl; R40 is specified in halogen, (C1-C4)-alkyl, phenyl-(C1-C4)-alkyl-, hydroxy, (C1-C4)-alkyl-O-, HO-CO-(C1-C4)-alkyl-O- and (C1-C4)-alkyl-O-CO-(C1-C4)-alkyl-O-, wherein all the substitutes R40 are independent from each other and may be identical or different; one of the groups Y1, Y2, Y3 and Y4 represents N, while the others are identical or different groups CH or CR40; n is specified in 0, 1, 2 and 3; p and q which are independent from each other and may be identical or different being specified in 2 and 3; n is specified in 0, 1 and 2, wherein all the values are independent from each other and may be identical or different; wherein all the alkyl groups are independently from each other optionally substituted by one or more fluorine atoms; wherein all the phenyl groups found in R and R40 are independently from each other optionally substituted by one or more identical or different substitutes specified in halogen and (C1-C4)-alkyl. Besides, the invention describes a method for preparing a compound of formula I, a pharmaceutical compositions having renin inhibitory activity and containing the compound of formula I and to using the compound of formula I for making a therapeutic preparation.
EFFECT: described and prepared are the new compounds that inhibit the enzyme renin, and modulate activity of the renin-angiotensin system, and are effective for treating the diseases such as, eg hypertension.
7 cl, 141 ex, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CYCLIC (AZA)INDOLYSINCARBOXAMIDES, PREPARING AND USING THEM AS PHARMACEUTICAL AGENTS | 2010 |
|
RU2539574C2 |
| BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | 2012 |
|
RU2662827C2 |
| FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | 2013 |
|
RU2650111C2 |
| NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITING NAMPT | 2011 |
|
RU2617643C2 |
| MODULATORS OF NUCLEAR RECEPTORS | 2016 |
|
RU2715897C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS KINASE 1β-ADRENERGIC RECEPTOR INHIBITORS | 2006 |
|
RU2415855C2 |
| BENZIMIDAZOLE AND IMIDAZO[4,5-c]PYRIDINE DERIVATIVES AS HEDGEHOG PATHWAY ANTAGONIST | 2010 |
|
RU2533825C2 |
| NEW AZAQUINOLINE DERIVATIVES | 2018 |
|
RU2773290C2 |
| ACTIVIN RECEPTOR-LIKE KINASE INHIBITORS | 2018 |
|
RU2788628C2 |
| SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE FOR TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2773333C2 |
